Aktieanalys

Cantargia: New Biomarker Results in Pancreatic Cancer - Redeye

{newsItem.title}

Redeye Publicerad: 15 Mar 2023 14:43

Redeye believes the new biomarker results with nadunolimab to be presented at the AACR Annual Meeting 2023 validate the scientific understanding of nadunolimab.

Länk till analysen i sin helhet: https://www.redeye.se/research/889793/cantargia-new-biomarker-results-in-pancreatic-cancer?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt